Division of Substance Dependence, Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado, USA.
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Medicine, Aurora, Colorado, USA.
Cannabis Cannabinoid Res. 2022 Feb;7(1):65-77. doi: 10.1089/can.2020.0002. Epub 2020 Jun 19.
Relatively little is known about the molecular pathways influenced by cannabis use in humans. We used a multi-omics approach to examine protein, metabolomic, and lipid markers in plasma differentiating between cannabis users and nonusers to understand markers associated with cannabis use. Eight discordant twin pairs and four concordant twin pairs for cannabis use completed a blood draw, urine and plasma toxicology testing, and provided information about their past 30-day cannabis use and other substance use patterns. The 24 twins were all non-Hispanic whites. Sixty-six percent were female. Median age was 30 years. Fifteen participants reported that they had used cannabis in the last 30 days, including eight participants that used every day or almost every day (29-30 of 30 days). Of these 15 participants, plasma 11-nor-9-carboxy-Δ-tetrahydrocannabinol (THC-COOH) and total tetrahydrocannabinol (THC) concentrations were detectable in 12 participants. Among the eight "heavy users" the amount of total THC (sum of THC and its metabolites) and plasma THC-COOH concentrations varied widely, with ranges of 13.1-1713 ng/mL and 2.7-284 ng/mL, respectively. A validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay measured plasma THC-COOH, THC, and other cannabinoids and metabolites. Plasma THC-COOH was used as the primary measure. Expression levels of 1305 proteins were measured using SOMAScan assay, and 34 lipid mediators and 314 metabolites were measured with LC-MS/MS. Analyses examined associations between markers and THC-COOH levels with and without taking genetic relatedness into account. Thirteen proteins, three metabolites, and two lipids were identified as associated with THC-COOH levels. Myc proto-oncogene was identified as associated with THC-COOH levels in both molecular insight and potential marker analyses. Five pathways (interleukin-6 production, T lymphocyte regulation, apoptosis, kinase signaling pathways, and nuclear factor kappa-light-chain-enhancer of activated B cells) were linked with molecules identified in these analyses. THC-COOH levels are associated with immune system-related pathways. This study presents a feasible approach to identify additional molecular markers associated with THC-COOH levels.
关于大麻使用影响的分子途径,人们知之甚少。我们采用多组学方法,检测区分大麻使用者和非使用者的血浆中的蛋白质、代谢组学和脂质标志物,以了解与大麻使用相关的标志物。 8 对不和谐双胞胎和 4 对和谐双胞胎完成了血液采集、尿液和血浆毒理学检测,并提供了他们过去 30 天大麻使用和其他物质使用模式的信息。这 24 对双胞胎均为非西班牙裔白人。66%为女性。中位年龄为 30 岁。15 名参与者报告在过去 30 天内使用过大麻,其中 8 名参与者每天或几乎每天(30 天中的 29-30 天)使用。在这 15 名参与者中,12 名参与者的血浆 11-去甲-9-羧基-Δ-四氢大麻酚(THC-COOH)和总四氢大麻酚(THC)浓度可检测到。在这 8 名“重度使用者”中,总 THC(THC 及其代谢物的总和)和血浆 THC-COOH 浓度差异很大,范围分别为 13.1-1713ng/mL 和 2.7-284ng/mL。一种经过验证的液相色谱-串联质谱(LC-MS/MS)测定法测量了血浆 THC-COOH、THC 和其他大麻素及其代谢物。使用血浆 THC-COOH 作为主要测量指标。使用 SOMAScan 测定法测量了 1305 种蛋白质的表达水平,并用 LC-MS/MS 测量了 34 种脂质介质和 314 种代谢物。分析考虑了在考虑和不考虑遗传相关性的情况下,标志物与 THC-COOH 水平之间的关联。 确定了 13 种蛋白质、3 种代谢物和 2 种脂质与 THC-COOH 水平相关。Myc 原癌基因在分子洞察和潜在标志物分析中均被确定与 THC-COOH 水平相关。这五个途径(白细胞介素-6 产生、T 淋巴细胞调节、细胞凋亡、激酶信号通路和核因子 kappaB 轻链增强子的激活 B 细胞)与这些分析中鉴定的分子相关联。 THC-COOH 水平与免疫系统相关途径相关。这项研究提出了一种可行的方法来识别与 THC-COOH 水平相关的其他分子标志物。